Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

• Status: Unknown status
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

1. The use of LMWH following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed.

2. The rates of clinically significant DVT will be equivalent between two groups.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Tennessee
• Treatments: Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• At least 18 years old

• Surgical ankle fracture able to be definitively treated with one operation

Exclusion Criteria:

• Younger than 18 years of age

• Other significant injury

• Known hypercoagulable state

• History of bleeding disorder

• History of DVT